World's Best Scientists 2026 revealed!
Henry S. Friedman

Henry S. Friedman

D-Index & Metrics

Medicine

D-Index
135
Citations
74816
World Ranking
2056
National Ranking
1164

Research.com Recognitions

  • 1971 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Henry S. Friedman is affiliated with Duke University in the United States and has contributed significantly to the field of medicine, specifically focusing on genetics, oncology, immunology, pulmonary and respiratory medicine, and radiology, nuclear medicine, and imaging.

Their research primarily revolves around glioma diagnosis and treatment, cancer immunotherapy and biomarkers, cancer research and treatments, brain metastases and treatment, immunotherapy and immune responses, nanoplatforms for cancer theranostics, and CAR-T cell therapy research.

Among the recent papers authored or co-authored by Henry S. Friedman are:

  • Management of glioblastoma: State of the art and future directions, 2020, CA A Cancer Journal for Clinicians
  • Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma, 2023, Journal of Clinical Oncology
  • Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy, 2021, Nature Communications
  • Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial, 2023, The Lancet Child & Adolescent Health
  • A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine, 2024, Nature Communications

Frequent co-authors collaborating with Friedman include Annick Desjardins, David M. Ashley, Katherine B. Peters, Margaret Johnson, and James E. Herndon. These collaborations highlight a network of research partnerships predominantly centered on oncology and related medical fields.

Friedman's work is often published in venues such as:

  • Neuro-Oncology
  • Journal of Clinical Oncology
  • Neuro-Oncology Advances
  • Neuro-Oncology Practice
  • Cancer Research

Henry S. Friedman's array of publications, co-authorships, and focus areas reflect an active engagement in advancing understanding and treatment options within oncology and related medical specialties.

In recognition of their professional contributions, Friedman was named a Fellow of the American Association for the Advancement of Science (AAAS) in 1971.

Best Publications

  • IDH1 and IDH2 Mutations in Gliomas

    Hai Yan;D. Williams Parsons;Genglin Jin;Roger McLendon

  • Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

    Henry S. Friedman;Michael D. Prados;Patrick Y. Wen;Tom Mikkelsen

  • Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jennifer Marcello

  • TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

    Patrick J. Killela;Zachary J. Reitman;Yuchen Jiao;Chetan Bettegowda

  • Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jeannette M. Dowell

  • A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

    W K A Yung;R E Albright;J Olson;R Fredericks

  • Temozolomide and treatment of malignant glioma.

    Henry S. Friedman;Tracy Kerby;Hilary Calvert

  • Postoperative Chemotherapy and Delayed Radiation in Children Less Than Three Years of Age With Malignant Brain Tumors

    Patricia K. Duffner;Marc E. Horowitz;Jeffrey P. Krischer;Henry S. Friedman

  • Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

    John H. Sampson;Amy B Heimberger;Gary E. Archer;Kenneth D. Aldape

  • Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse

    W. K.Alfred Yung;Michael D. Prados;Ricardo Yaya-Tur;Steven S. Rosenfeld

  • Phase II Trial of Gefitinib in Recurrent Glioblastoma

    Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell

  • Recurrent glioblastoma treated with recombinant poliovirus

    Annick Desjardins;Matthias Gromeier;James E. Herndon;Nike Beaubier

  • The Genetic Landscape of the Childhood Cancer Medulloblastoma

    D. Williams Parsons;D. Williams Parsons;Meng Li;Xiaosong Zhang;Siân Jones

  • Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

    Yuchen Jiao;Patrick J. Killela;Zachary J. Reitman;B Ahmed Rasheed

  • Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study.

    Peter C. Burger;I. T. Yu;Tarik Tihan;Henry S. Friedman

  • Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

    Duane A. Mitchell;Kristen A. Batich;Michael D. Gunn;Min-Nung Huang

  • PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

    B. K. Ahmed Rasheed;Timothy T. Stenzel;Roger E. McLendon;Ramon Parsons

  • The pediatric preclinical testing program: description of models and early testing results.

    Peter J. Houghton;Christopher L. Morton;Chandra Tucker;Debbie Payne

  • Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study.

    R K Mulhern;J L Kepner;P R Thomas;F D Armstrong

  • TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL

    Hai Yan;P.J. Killela;Z.J. Reitman;Y. Jiao

Frequent Co-Authors

Darell D. Bigner
Darell D. Bigner Duke University
James E. Herndon
James E. Herndon Duke University
Allan H. Friedman
Allan H. Friedman Duke University
Roger E. McLendon
Roger E. McLendon Duke University
John H. Sampson
John H. Sampson Duke University
David A. Reardon
David A. Reardon Harvard University
James J. Vredenburgh
James J. Vredenburgh Yale School of Medicine
Jeremy N. Rich
Jeremy N. Rich University of Pittsburgh
Larry E. Kun
Larry E. Kun St. Jude Children's Research Hospital
Joanne Kurtzberg
Joanne Kurtzberg Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering an alternative route or supplement to studying Medicine in the USA? There are a growing number of online degrees and accelerated pathways in healthcare. For nurses looking to advance quickly, explore the fastest dnp online program options. These programs allow registered nurses to earn a Doctor of Nursing Practice in less time than traditional routes.

If flexibility and accessibility are concerns, you may want to review programs recognized as the easiest dnp program reddit users recommend. These programs prioritize approachable coursework and manageable prerequisites for working professionals.

Those seeking the quickest entry into the healthcare workforce often ask, what is the fastest way to become an lpn? Online and hybrid LPN programs speed up the timeline significantly—ideal if you want to begin hands-on patient care sooner.

Mental health is another booming field. For RNs hoping to specialize, pmhnp online programs offer streamlined pathways to becoming a Psychiatric Mental Health Nurse Practitioner.

Each of these online healthcare options offers unique benefits to suit different career goals and timelines within medicine.

Best Scientists Citing Henry S. Friedman

Trending Scientists